Pediatric Myopia

The FDA accepted a new drug application for SYD-101 to slow the progression of pediatric myopia and assigned a Prescription Drug User Fee Act date of Oct. 23, according to a press release from Sydnexis.

The FDA has granted breakthrough device designation to SightGlass Vision’s diffusion optics technology spectacle lenses, which are designed to slow myopia progression in children.

WAILEA, Hawaii — In this Healio video perspective from Hawaiian Eye 2024, Nick Ruth, MBA, of Sydnexis, delivers an update on SYD-101, the company’s upcoming treatment for progressive myopia in pediatric patients.

Research into effective treatments for myopic progression expands beyond contact lenses and involves atropine, red light therapy and spectacle lenses, as Healio has reported throughout 2023.

SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, Nick Ruth, MBA, of Sydnexis previews upcoming data for a progressive myopia treatment for pediatric patients.

SAN FRANCISCO — A low-dose, preservative-free formulation of atropine is effective in slowing myopia progression in children aged 3 to 17 years, according to phase 3 data presented here.

Dopavision has completed enrollment for its MyopiaX-1 trial, a randomized active-controlled study of the light-based digital treatment for children and adolescents with myopia, the company announced in a press release.

Vyluma Inc. has announced that the FDA will review its new drug application for NVK002, a preservative-free, low-dose atropine eye drop for myopia in children aged 3 to 17 years.

DENVER — A study used census data to find a high prevalence of pediatric myopia in the United States, including a disparity between urban and rural children.

GoCheck, creator of the GoCheck Kids platform designed to screen for vision conditions in children at younger ages, announced $10 million in new funding, according to a press release.